Beilstein J. Nanotechnol.2019,10, 1002–1015, doi:10.3762/bjnano.10.101
serum; nanoparticles; poly(lactide-co-glycolicacid); protein corona; proteomics; Introduction
Nanoparticle (NP)-based drug carrier systems offer outstanding opportunities in the treatment of many serious diseases. The unique physicochemical properties and the ability to bind a library of ligands make
PDF
Figure 1:
SEM confirmed the spherical shape of the PLGA NPs and the smoothness of the surface.